

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/46, 45/06, A61P 19/00, 29/00		A1	(11) International Publication Number: WO 00/48597
			(43) International Publication Date: 24 August 2000 (24.08.00)
(21) International Application Number: PCT/EP00/01268			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 16 February 2000 (16.02.00)			
(30) Priority Data: 9903755.8 18 February 1999 (18.02.99) GB 9914947.8 25 June 1999 (25.06.99) GB			
(71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).			
(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).			
(72) Inventors; and (75) Inventors/Applicants (for US only): FÄRBER, Lothar [DE/DE]; Drosselweg 6, D-90562 Heroldsberg (DE). MÜLLER, Wolfgang [CH/CH]; Im Rehwechsel 30, CH-4102 Binningen (CH). STRATZ, Thomas [DE/DE]; Purkersdorferstrasse 49, D-79713 Bad Säckingen (DE).			
(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).			Published With international search report.
(54) Title: SYSTEMIC USE OF 5-HT ₃ RECEPTOR ANTAGONISTS AGAINST RHEUMATIC INFLAMMATORY PROCESSES			
(57) Abstract The present invention relates to a new use for compounds having 5-HT ₃ (serotonin M) receptor antagonist activity, especially tropisetron, for the manufacture of a pharmaceutical composition for the systemic treatment of an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SYSTEMIC USE OF 5-HT₃ RECEPTOR ANTAGONISTS AGAINST RHEUMATIC INFLAMMATORY PROCESSES

The present invention relates to a new use, in particular a new pharmaceutical use for compounds having 5-HT₃ (serotonin M) receptor, in particular specific 5-HT₃ receptor, antagonist activity, especially in the manufacture of a pharmaceutical composition.

The 5-HT₃-receptor antagonists comprise a defined and recognised class of pharmaceutically active compounds well known in the art and characterised, as their name implies, by their pharmacological activity. Various 5-HT₃ receptor antagonist compounds are commercially available and clinically applied, e.g. in the treatment of emesis:

In accordance with the present invention it has now surprisingly been found that 5-HT₃ receptor antagonists are useful for the systemic treatment of inflammatory rheumatic or rheumatoid diseases other than crystal induced arthritis, especially gout, and from living pathogen induced inflammatory diseases as long as the living pathogen is still present, especially of inflammation, e.g. of inflammatory processes, conditions, events and disease as well as their sequelae or symptoms, associated with rheumatic or rheumatoid diseases.

Hence, the present invention relates to the use of a 5-HT₃ receptor antagonist or of a pharmaceutically acceptable salt of such an antagonist for the manufacture of a pharmaceutical composition for the systemic treatment of an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present, for example the treatment of any process, condition, event, or disease as hereinafter described. In particular, the present invention provides the use as mentioned before where, in addition to pain, at least one further sequela or symptom in addition to pain that is associated with the inflammatory rheumatoid or rheumatic disease is alleviated, ameliorated or controlled.

Any 5-HT₃ receptor antagonist can be used in accordance with the invention. Preferred 5-HT₃ receptor antagonists which may be employed in accordance with the present invention are:

- A) Ondansetron [1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one (cf. Merck Index, twelfth edition, item 6979);
- B) Granisetron [endo-1-methyl-N-(9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-1H-imidazole-3-carboxamide: (cf. loc. cit., item 4557); and
- C) Dolasetron [1H-indole-3-carboxylic acid (2 α , 6 α , 8 α , 9 $\alpha\beta$)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester] (cf. loc. cit., item 3471).

Particular 5-HT₃ receptor antagonists which may be employed in accordance with the present invention are those of the formula 1 as defined in European Patent Publication 189002 B1, the contents of which are incorporated herein by reference, in particular the compound:

- D) Indol-3-yl-carboxylic acid-endo-8-methyl-8-aza-bicyclo[3,2,1]-oct-3-yl-ester, also known as tropisetron. (cf. loc.cit., item 9914).

Further 5-HT₃ receptor antagonists which may be used preferably in accordance with the present invention are:

- E) 4,5,6,7-tetrahydro-5-[(1-methyl-indol-3-yl)carbonyl]benzimidazole (see also ramosetron, see U.S. patent 5,344,927);
- F) (+)-10-methyl-7-(5-methyl-1H-imidazol-4-ylmethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-6-one (see also fabesetron, EP 0 361 317); and
- G) [N-(1-ethyl-2-imidazolin-2-yl-methyl)-2-methoxy-4-amino-5-chlorobenzamide (see also lintopride - Chem.- Abstr.-No. 107429-63-0).

A further 5-HT₃ receptor antagonists which may be used preferably in accordance with the present invention is

- (H) 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one (see also alosetron, EP 0 306 323).

Each of these compounds, alone or in combination with one or more other 5-HT₃ inhibitor, may be used for the treatment according to the invention.

For use in accordance with the present invention tropisetron (especially in the formulation called NAVOBAN®) is most preferred.

5-HT₃-receptor antagonists may be employed in accordance with the invention in free or in pharmaceutically acceptable salt form, e.g. as known in the art, for example, in the case of compounds A) to D) above in pharmaceutically acceptable acid addition salt form, for example, in the case of: compound A) the hydrochloride dihydrate; compound B) the hydrochloride; compound C) the mesylate; and compound D) the monohydrochloride. References to 5-HT₃ receptor antagonists collectively or individually throughout the present specification and claims are accordingly to be understood as embracing both free compounds and such pharmaceutically acceptable salt forms, e.g. as clinically employed, and further also solvates, e.g. hydrates, or specific crystal forms of any of these compounds or salts.

Thus, the invention relates to the use of a 5-HT₃ receptor antagonist or of a pharmaceutically acceptable salt of such an antagonist for the manufacture of a pharmaceutical composition for the systemic treatment of an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present, where the 5-HT₃ receptor antagonist is selected from the group consisting of ondansetron, granisetron, dolasetron, tropisetron, ramosetron, fabesetron, lintopride and alosetron, which may be used in free form, that is, not as a salt, or as a pharmaceutically acceptable salt.

In accordance with the present invention it has now surprisingly been found that 5-HT₃ receptor antagonists are useful for the treatment of inflammation. They are useful for the treatment of inflammatory rheumatic or rheumatoid processes, conditions or events, for example, consequential to disease (including infection, for example viral infection, with the proviso that in case of an acute infection or parasite infestation, e.g. bacterial, fungal or, in a broader sense, viral or protozoal infection, or infestation by a parasite, first treatment of the infection or infestation itself, e.g. with antibiotics or other treatment, is indicated to

remove the living pathogen before the 5-HT₃ antagonist is used), as well for the treatment of inflammatory disease as such.

"Treatment" as used herein includes systemic use for the alleviation, amelioration or control of inflammation, e.g. of inflammatory rheumatic or rheumatoid disease, process, condition or event. It also includes intervention for the alleviation, amelioration or control of the sequelae or symptoms of inflammation, for example degeneration (e.g. of cells, epithelia or tissues), or especially swelling, exudation or effusion, or pain. In this context the term "treatment" is further to be understood as embracing use to reverse, restrict or control progression of any specified disease, process, condition, event or the like, including use for disease modifying effect. If any of the mentioned diseases, processes, conditions or events is associated with pain, the term "treatment" preferably encompasses the alleviation, amelioration or control (including temporal or permanent removal) of at least one further sequela or symptom in addition to pain, such as swelling, effusion, exsudation, stiffness, lack of flexibility of joints, or degeneration, more preferably of all symptoms and most preferably of the total clinical picture of the respective disease, irritation or manifestation.

The present invention is in particular applicable to the systemic treatment of an inflammatory disease other than crystal induced arthritis (gout) or preferably other than living pathogen induced inflammation as long as the living pathogen is still present, especially of manifestations at the locomotor apparatus, such as various inflammatory rheumatoid diseases (except for crystal induced arthritis (e.g. gout) and living pathogen induced diseases as long as the pathogen (e.g. a virus, bacterium, fungus, protozoon or parasite) is still present, so that causal treatment against the pathogen is indicated first, such as

- (1) chronic polyarthritis (= rheumatoid arthritis), including juvenile arthritis or psoriasis arthropathy;
- (2) paraneoplastic syndrome or tumor-induced inflammatory diseases,
- (3) turbid effusions,
- (4) collagenosis, such as systemic Lupus erythematosus, poly-myositis, dermato-myositis, systemic scleroderma or mixed collagenosis;
- (5) postinfectious arthritis (where no living pathogenic organism can be found at or in the affected part of the body), or
- (6) seronegative spondylarthritis, such as spondylitis ankylosans;

or further

(7) vasculitis,

(8) sarcoidosis, or

(9) arthrosis;

or further any combinations thereof.

An example of a preferred inflammation to be treated systemically is

- (a) synovial inflammation, for example, synovitis, including any of the particular forms of synovitis recited in Dorland's Illustrated Medical Dictionary, 26th edition, pub. W. B. Saunders and Co. at page 1301, in particular bursal synovitis and purulent synovitis, as far as it is not crystal-induced. Such synovial inflammation may for example, be consequential to or associated with disease, e.g. arthrosis, including arthritis, e.g. osteoarthritis, rheumatoid arthritis or arthritis deformans.

The present invention is further applicable to the systemic treatment of:

- b) Inflammation, e.g. inflammatory diseases or conditions, of the joints or locomotor apparatus in the region of the tendon insertions and tendon sheaths.

Such inflammation may, for example, be consequential to or associated with disease or further (in a broader sense of the invention) with surgical intervention, e.g. as recited under a) above, including, in particular conditions such as insertion endopathy, myofasciale syndrome and tendomyosis.

The present invention is especially applicable to the treatment of:

- c) Inflammation, e.g. inflammatory disease or condition, of connective tissues.

Such diseases or conditions include in particular dermatomyositis and myositis.

From the foregoing it will be understood that the present invention is to be further understood as embracing the systemic treatment, e.g. therapy, of any disease or condition as set forth above, for example arthrosis, dermatomyositis etc., for example, for the alleviation or control of inflammatory processes or events and their sequelae associated therewith or consequential thereto, e.g. for the treatment of rheumatoid arthritis, e.g. to alleviate or control joint inflammation or effusion.

In the case of the inflammatory diseases, diseases where a living pathogen, e.g. a virus, a bacterium, a fungus, a protozoon or a parasite or the like, is still present, the treatment of must first aim at removal of the pathogen causative for the disease, before treatment with a 5-HT₃ antagonist is used, as otherwise there is the danger that the causative pathogen remains intact. Then the mere symptomatic treatment with a 5-HT₃ antagonist is contraindicated in order to avoid survival or even further spread of the causative infection. This is also valid in the case of combination with an anti-inflammatory glucocorticosteroid as described in the following, as is the proviso that treatment of crystal-induced inflammation is excluded.

In a further aspect it has been found in accordance with the present invention that systemic administration of 5-HT₃ receptor antagonists is useful as replacement therapy for anti-inflammatory glucocorticosteroid, e.g. cortisone or the like, therapy. For example for use in any means of treatment as hereinbefore set forth.

The term "replacement therapy" as used herein is to be understood as embracing both use "as full replacement", i.e. use instead of anti-inflammatory glucocorticosteroid therapy, as well as use "as partial replacement" for anti-inflammatory glucocorticosteroid therapy, i.e. for administration together with anti-inflammatory glucocorticosteroid therapy or as a means of reducing glucocorticosteroid dosage or to achieve a glucocorticosteroid sparing effect.

The present invention accordingly provides:

- I. A method of treating inflammation, for example treating any process, condition, event, or disease as hereinbefore set forth, in a subject in need thereof, which method comprises administering systemically an effective amount of a 5-HT₃ receptor antagonist;
- II. A method of providing replacement therapy for anti-inflammatory glucocorticosteroid therapy in a subject receiving such glucocorticosteroid therapy, for example for or in the treatment of any process, condition, event or disease as hereinbefore set forth, which process comprises systemically administering to said subject an effective

amount, e.g. an anti-inflammatory glucocorticosteroid sparing amount, of a 5-HT₃-receptor antagonist; as well as

- III. A method of treating inflammation, for example treating any process, condition, event or disease as hereinbefore set forth, in a subject in need thereof, which method comprises systemically administering an effective amount of a 5-HT₃ receptor antagonist together with an anti-inflammatory glucocorticosteroid.

Where co-administration is practiced as under III above the drug substances, i.e. 5-HT₃ receptor antagonist and anti-inflammatory glucocorticosteroid may be administered sequentially or simultaneously or substantially simultaneously, e.g. employing a fixed combination dosage form.

In further aspects the present invention also provides:

- IV. A 5-HT₃ receptor antagonist for use in, or for use in the manufacture of a pharmaceutical composition for use in; or the use of a pharmaceutical composition comprising a 5-HT₃ receptor antagonist for systemic use:
- a) in the treatment of inflammation, for example any inflammatory process, condition, event or disease as hereinbefore set forth;
 - b) as replacement therapy for anti-inflammatory glucocorticosteroid therapy, for example in the treatment of any inflammatory process, condition, event or disease as hereinbefore set forth; or
 - c) for co-administration together with an anti-inflammatory glucocorticosteroid in the treatment of inflammation, for example in the treatment of any inflammatory process, condition, event or disease as hereinbefore set forth; as well as
- V. A pharmaceutical dosage form for systemic administration comprising a 5-HT₃ receptor antagonist together with an anti-inflammatory glucocorticosteroid.

The terms "systemically administering" or "systemic use" refer to a way of administration that is not local (= at or near the site of a disease manifestation), but that leads to exposure of most or all of the parts of the body to the 5-HT₃-antagonist.

Dosage forms in accordance with V above are to be understood as including both fixed-unit-dosage forms, e.g. tablets, capsules, liquid formulations and the like comprising both active ingredients together with appropriate pharmaceutically acceptable diluents or carriers, as well as twin delivery systems, packages or the like comprising both active ingredients separately or in separate dosage form, for concomitant or sequential administration.

Utility of 5-HT₃ receptor antagonists in accordance with the present invention can be demonstrated in clinical trials carried in accordance with standard techniques and methodologies, for example as follows:

The following examples are for illustrative purposes and are not intended to diminish the scope of the present invention. Instead of tropisetron, any other 5-HT₃-antagonist, or a pharmaceutically acceptable salt thereof, solvate, e.g. hydrate, or crystalline form thereof, especially selected from the group consisting of ondansetron, granisetron, dolasetron, ramosetron, fabesetron, lintopride and alosetron, can be used, or any combination of two or more of these 5-HT₃ receptor antagonists or pharmaceutically acceptable salts thereof.

EXAMPLE 1: Treatment of synovial inflammation/synovitis consequent to inflammatory processes

Trials are performed on a patient exhibiting rheumatoid arthritis and severe consequential synovial inflammation as well as marked pain.

The patient had previously been treated, largely unsuccessfully, with methotrexate, azathioprin and cyclosporin and at entry into the trial exhibits severe synovial swelling in particular of the finger joints, the wrist and in the knee joint (accompanied by effusion or exudation). The subject is treated for 5 days sequentially with tropisetron administered at a dose of 2 mg/day i.v. Treatment results in amelioration of the synovial inflammation, a reduction of stiffness in the morning and remission from the formation of effusion in the kneejoint. There is a reduction of the measure parameters for inflammation as well as a marked reduction of glucocorticoid requirements.

EXAMPLE 2: Treatment of synovial inflammation

A patient exhibits damage to the meniscus of the right knee joint as well as arthritic change leading to synovial inflammation with consequential knee joint effusion. Despite a successful synovialectomy prior to trial entry the patient exhibits renewed knee joint effusion. Two 2 mg doses of tropisetron are administered i.v. over a period of 17 days with 15 injections, one each day with a 2 days pause in therapy. 24 hours after the first i.v. injection, significant improvement of pain is reported. Following continuation of injections, the patient exhibits as virtually free of symptoms. The exudation from the knee joint is completely inhibited without any other medication within 8 days and movement of the knee joint is clearly improved. The improvement in condition continues over a further 7 days observation following completion of therapy.

EXAMPLE 3: Treatment of dermatomyositis/vasculitis

A patient exhibiting marked dermatomyositis with accompanying bioptically verified vasculitis receives 3 injections i.v., each of 2 mg tropisetron. Virtually complete remission of the massive reddening of the skin and a clear reduction of pain symptoms is observed, already after the first injection. The patient remains substantially complaint free over a period of one week following indicating effective control of inflammatory event.

Equivalent results are obtainable in equivalent or comparable trials with patients exhibiting similar symptomatology employing 5-HT₃-receptor antagonists other than tropisetron, for example using any of the 5-HT₃-receptor antagonists A) through C) or E) through H) hereinbefore recited at comparable, e.g. conventional clinical, dose as known in the art. Similar results are also achievable employing 5-HT₃-receptor antagonists, e.g. tropisetron at doses of the order of 2 mg/day p.o. or by injection or topical application in clinical trials involving subjects exhibiting other inflammatory diseases, conditions or symptoms as herein specified.

Trials conducted as described above or analogously are demonstrative of long lasting and disease modifying effects in conditions herein described as well as symptomatic and anti-inflammatory glucocorticosteroid replacement effect for 5-HT₃ receptor antagonists.

For use in accordance with the present invention the appropriate dosage will, of course, vary depending on for example the particular 5-HT₃ receptor antagonist employed the mode of administration and the nature and severity of the condition to be treated as well as the specific condition to be treated. In general an indicated daily dosage will be in the range usually employed for known indications such as emesis and will typically be from about 0.05 to about 50 mg per day conveniently administered once or in divided doses up to four times a day or in sustained release form. In the case of tropisetron an appropriate dosage for administration, e.g. by injection, for example for i.v. application or injection direct into the tissues, will be of the order of 2 mg or up to and including 5 mg per day, administered once, sequentially over a sequence of 2 to 20 days or at intervals of 2 to 5 days to 2 days to 2 weeks.

For use in accordance with the invention, 5-HT₃ receptor antagonists may be administered systemically by any conventional route in particular enterally, preferably orally, e.g. in the form of tablets or capsules, or via suppositories or or most preferably parenterally, e.g. in the form of injectible solutions or suspensions, for intravenous, intra-muscular (not for local but for systemic treatment), sub-cutaneous (not for local but for systemic treatment) or intra-peritoneal administration, or for infusion. In the case of intravenous administration bolus injection is preferred. Suitable formulations for use in accordance with the present invention will include any of those as known and commercially available and employed in clinic in the art. By systemical administration, it is meant that the administration is not at or near the site of a disease manifestation with the goal to reach a higher local concentration of the administered 5-HT₃ receptor antagonist at that site (though it may not be possible to avoid this, e.g. where the whole body is affected), but aims at systemic exposure of most of or all of the body, generally also including the site of administration.

CLAIMS

1. The use of a 5-HT₃ receptor antagonist or of a pharmaceutically acceptable salt of such an antagonist for the manufacture of a pharmaceutical composition for the systemic treatment of an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present.
2. The use according to claim 1 where, in addition to pain, at least one further sequela or symptom that is associated with the inflammatory rheumatoid or rheumatic disease is alleviated, ameliorated or controlled.
3. The use according to claim 1 or claim 2, where the 5-HT₃ receptor antagonist is selected from the group consisting of ondansetron, granisetron, dolasetron, tropisetron, ramosetron, fabesetron, lintopride and alosetron or the pharmaceutically acceptable salts of such antagonists.
4. The use according to any one of claims 1, wherein the disease to be treated is a disease other than crystal induced arthritis and is selected from the group consisting of
 - (1) chronic polyarthritis,
 - (2) paraneoplastic syndrome or tumor-induced inflammatory diseases,
 - (3) turbid effusions,
 - (4) collagenosis,
 - (5) postinfectious arthritis,
 - (6) seronegative spondylarthritis,
 - (7) vasculitis,
 - (8) sarcoidosis, and
 - (9) arthrosis.
5. The use according to any one of claims 1, wherein the disease to be treated is a disease other than crystal induced arthritis and is selected from the group consisting of
 - (1) chronic polyarthritis,

- (2) paraneoplastic syndrome or tumor-induced inflammatory diseases,
 - (3) turbid effusions,
 - (4) collagenosis,
 - (5) postinfectious arthritis, and
 - (6) seronegative spondylarthritis.
6. A method of systemically treating an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present in a subject in need thereof, which method comprises administering to said subject an effective amount of a 5-HT₃ receptor antagonist.
7. A method of providing replacement therapy for anti-inflammatory glucocorticosteroid therapy in a subject receiving such glucocorticosteroid therapy, which process comprises systemically administering to said subject an effective amount of a 5-HT₃-receptor antagonist.
8. A method of treating inflammation in a subject in need thereof, which method comprises systemically administering an effective amount of a 5-HT₃ receptor antagonist together with an anti-inflammatory glucocorticosteroid.
9. A 5-HT₃ receptor antagonist or a pharmaceutical composition comprising a 5-HT₃ receptor antagonist for systemic use:
- a) in the treatment of any inflammatory process, condition, event or disease as hereinbefore described;
 - b) as replacement therapy for anti-inflammatory glucocorticosteroid therapy in the treatment of any inflammatory process, condition, event or disease as hereinbefore described; or
 - c) for co-administration together with an anti-inflammatory glucocorticosteroid in the treatment of any inflammatory process, condition, event or disease as hereinbefore described.
10. A pharmaceutical dosage form for systemical administration comprising a 5-HT₃ receptor antagonist together with an anti-inflammatory glucocorticosteroid.

11. A method, use or pharmaceutical dosage form as claimed in any one of claims 1 to 10, wherein the 5-HT₃ receptor antagonist is tropisetron.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/01268

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/46 A61K45/06 A61P19/00 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 36586 A (SMITHKLINE BEECHAM PLC ;BLOWER PETER ROBIN (GB)) 9 October 1997 (1997-10-09) page 5; claim 3	9
X	CUNNINGHAM D ET AL: "Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam." ANNALS OF ONCOLOGY, (1996 MAR) 7 (3) 277-82., XP000886538 page 278; table 1	10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

19 May 2000

Date of mailing of the international search report

26/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Brunnauer, H

INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/EP 00/01268

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DOAK G J ET AL: "Formalin-induced nociceptive behavior and edema: involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes." NEUROSCIENCE, (1997 OCT) 80 (3) 939-49. , XP000886556 abstract page 946, left-hand column	7,8
Y	ROSENSTEIN D.M. ET AL: "Antinoiceptive effects of microdialysis administration of 5-HT-1A and 5-HT-3 Receptor Agonists and Antagonists in a model of acute arthritis" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, 1997, page 1540 XP000886228 abstract	7,8
A	BLANCO R. GAONZALEZ-GAY MA. ET AL: "Ondansetron therapy is useful in refractory and severe methotrexate-induced nausea in rheumatoid arthritis" BRITISH JOURNAL OF RHEUMATOLOGY, vol. 37, 1998, page 117 XP000886199 abstract	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/01268

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9736586 A	09-10-1997	AU 2290597 A ZA 9702684 A	22-10-1997 28-09-1998